Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Almost all anthropometric variables were higher in the treatment group than in the comparative group (p < 0.05) regardless of the sex, with the exception of muscle mass (both sexes) and waist-to-hip ratio (males) (Table 2).Baseline findings for the treatment group (liraglutide) and the control group (sibutramine).FemalepMalepControl (n = 26)Liraglutide (n = 24)Control (n = 20)Liraglutide (n = 33)Clinical findings Age (years)46 ± 1046 ± 90.85243 ± 1142 ± 110.657 SAP (mmhg)121 ± 5.7129.8 ± 14.30.008121.5 ± 7.1129.8 ± 9.90.002 DAP (mmhg)80.6 ± 4.381.3 ± 80.71679 ± 4.584.8 ± 5.8 < 0.001Anthropometric findings Body weight (kg)81 ± 892 ± 120.001103 ± 20117 ± 180.016 Muscle mass (kg)24.2 ± 4.525.3 ± 3.30.3537.4 ± 5.639.3 ± 4.20.16 Fat mass (kg)37.2 ± 6.845.7 ± 8.9 < 0.00137.3 ± 13.847.8 ± 14.50.012 BMI (kg/m2)28.2 ± 2.936.3 ± 3.9 < 0.00130.6 ± 438.3 ± 5.80.008 AC (cm)99.7 ± 6.9109.9 ± 10 < 0.001114.5 ± 15.7128.5 ± 14.50.002 WHR1 ± 01 ± 0.10.0081.1 ± 0.11.1 ± 0.10.23Bioimpedance FM%45.9 ± 5.749.7 ± 4.90.01635.3 ± 6.340.1 ± 7.10.016 LMA-R (kg)2.1 ± 0.52.5 ± 0.50.0143.4 ± 13.8 ± 0.90.152 LMA-L (kg)2.1 ± 0.52.5 ± 0.50.0263.5 ± 0.93.9 ± 0.80.17 LMT (kg)17 ± 4.419.6 ± 4.20.03624.4 ± 8.226.9 ± 6.80.228 LML-R (kg)5.9 ± 0.96.6 ± 1.20.0258.6 ± 2.19.2 ± 1.90.279 LML-L (kg)6 ± 16.6 ± 1.20.0378.6 ± 2.29.2 ± 1.90.281 FMA-R (kg)3.1 ± 1.24 ± 1.20.0052.9 ± 1.64.4 ± 20.004 FMA-L (kg)2.9 ± 14.1 ± 1.20.0012.9 ± 1.64.4 ± 20.003 FMT (kg)19.3 ± 4.124.1 ± 4.9 < 0.00120.6 ± 6.825.8 ± 5.90.005 FML-R (kg)5.7 ± 1.16.9 ± 1.50.0035.5 ± 2.17 ± 2.50.028 FML-L (kg)5.8 ± 1.27 ± 1.60.0035.5 ± 2.17 ± 2.50.03Laboratory findings Fasting glycemia (mg/dL)96.7 ± 10.2100.2 ± 15.70.34495.5 ± 9.498.2 ± 16.40.509 Insulin (µU/mL)12.2 (9.4 to 20.4)20.7 (9.4 to 26.5)0.17117.5 (10.5 to 22)20.2 (13.9 to 27)0.132 HOMA-IR2.71 (2.01 to 4.9)5.47 (2.25 to 6.7)0.1164.24 (2.42 to 5.35)4.89 (3.4 to 6.7)0.125 Total cholesterol (mg/dL)197.3 ± 40.5205.4 ± 46.60.514190.7 ± 63.5189.2 ± 40.10.918 LDL (mg/dL)127.1 ± 38127.8 ± 420.953132.4 ± 44.2121.7 ± 39.60.369 HDL (mg/dL)46.3 ± 11.157.2 ± 21.80.03444.1 ± 21.544.2 ± 15.20.982 Triglycerides (mg/dL)178.8 ± 56207.3 ± 80.50.156220.7 ± 80.7202.9 ± 71.10.406 TGO (U/L)27.5 (23 to 32)22.5 (16.5 to 27.5)0.02126 (22 to 30.5)34 (28 to 44)0.016 TGP (U/L)25 (22 to 31)28 (18 to 41.5)0.80030 (24.5 to 41)46 (28 to 71)0.022 Urea (mg/dL)31.7 ± 9.127.7 ± 80.10136.2 ± 5.133.5 ± 8.40.219 Creatinine (mg/dL)0.77 ± 0.170.77 ± 0.140.9700.94 ± 0.150.92 ± 0.180.603 Vitamin D (ng/mL)29.8 ± 10.826.9 ± 9.90.33332.5 ± 14.625.6 ± 7.60.061 ESR (mm/h)11.5 (7 to 17)12 (9 to 18)0.25016 (11.5 to 22)17 (9 to 21.5)0.748 CRP (mg/dL)0.29 (0.08 to 0.72)0.77 (0.41 to 2.01)0.0050.28 (0.14 to 0.94)0.63 (0.3 to 1.11)0.128 TSH (U/L)2.37 ± 1.11.82 ± 0.790.0451.8 ± 0.671.91 ± 0.770.598 Glycated hemoglobin (%)5.4 ± 0.55.8 ± 0.90.0955.5 ± 0.55.8 ± 1.30.281 Uric acid (mg/dL)4.7 ± 14.7 ± 1.30.8086 ± 1.36.7 ± 1.70.122Continuous variables expressed as mean ± standard deviation or median and interquartile range (in parenthesis).

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Non-randomised intervention study.

Non-randomised intervention study

Examines an intervention without random allocation.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

In this prospective non-randomized intervention study, we evaluated the effect of 6 months of treatment with liraglutide (n = 57) on the clinical, laboratory and BIA findings of adult sex-stratified patients diagnosed with obesity and MetS, compared to a control group receiving sibutramine (n = 46).

Source: Abstract.

Patients were selected by convenience sampling and participants in both groups were aware of the medication received.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome

Non-randomised intervention study · Scientific Reports · 2023

Original publication title

Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome

Frederico Perboyre Carioca Freitas; Carlos Ewerton Maia Rodrigues

© The Author(s) 2023

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Metabolic syndrome (MetS) and obesity represent a public health problem worldwide. Bioelectrical impedance analysis (BIA) is a practical and effective way of evaluating body composition, especially abdominal fat. Liraglutide, a GLP-1 analog, reduces body weight and improves cardiometabolic parameters. In this prospective non-randomized intervention study, we evaluated the effect of 6 months of treatment with liraglutide (n = 57) on the clinical, laboratory and BIA findings of adult sex-stratified patients diagnosed with obesity and MetS, compared to a control group receiving sibutramine (n = 46).

The groups were statistically similar with regard to the age of females (p = 0.852) and males (p = 0.657). Almost all anthropometric and BIA variables were higher in the treatment group than in the comparative group (p < 0.05). Abdominal circumference (AC) decreased significantly more in the treatment group. In males, body weight and fat mass also decreased (p < 0.05). Liraglutide treatment was associated with a greater reduction in trunk fat mass (FMT) (p < 0.05).

AC and FMT were strongly correlated (rho = 0.531, p < 0.001) in the treatment group. In the multiple regression analysis, liraglutide treatment remained independently associated with FMT. Treatment with liraglutide for 6 months promoted weight loss, improved cardiometabolic and inflammatory parameters and led to a significant reduction in FMT correlated with AC in obese MetS patients of both sexes.

Authors’ abstract

Metabolic syndrome (MetS) and obesity represent a public health problem worldwide. Bioelectrical impedance analysis (BIA) is a practical and effective way of evaluating body composition, especially abdominal fat. Liraglutide, a GLP-1 analog, reduces body weight and improves cardiometabolic parameters. In this prospective non-randomized intervention study, we evaluated the effect of 6 months of treatment with liraglutide (n = 57) on the clinical, laboratory and BIA findings of adult sex-stratified patients diagnosed with obesity and MetS, compared to a control group receiving sibutramine (n = 46).

The groups were statistically similar with regard to the age of females (p = 0.852) and males (p = 0.657). Almost all anthropometric and BIA variables were higher in the treatment group than in the comparative group (p < 0.05). Abdominal circumference (AC) decreased significantly more in the treatment group. In males, body weight and fat mass also decreased (p < 0.05). Liraglutide treatment was associated with a greater reduction in trunk fat mass (FMT) (p < 0.05).

AC and FMT were strongly correlated (rho = 0.531, p < 0.001) in the treatment group. In the multiple regression analysis, liraglutide treatment remained independently associated with FMT. Treatment with liraglutide for 6 months promoted weight loss, improved cardiometabolic and inflammatory parameters and led to a significant reduction in FMT correlated with AC in obese MetS patients of both sexes.

Publication and source details

Original title: Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome

Frederico Perboyre Carioca Freitas; Carlos Ewerton Maia Rodrigues

Scientific Reports · 2023

© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T16:57:56.709631+00:00

DOI: 10.1038/s41598-023-40366-4 · PMC10421848